Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2
- 1 September 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (9) , 1026-1031
- https://doi.org/10.1097/jto.0b013e318183aa1f
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Erlotinib in non-small-cell lung cancerExpert Opinion on Pharmacotherapy, 2007
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional StudyJNCI Journal of the National Cancer Institute, 2007
- Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?British Journal of Cancer, 2007
- Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non–Small-Cell Lung Cancer Patients: ECOG 1599Journal of Clinical Oncology, 2007
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and FluorescenceIn situHybridization—Why, When, and How?Clinical Cancer Research, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non-Small Cell Lung CancerThe Oncologist, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000